FLUOGUIDE A/S DK -1 (96X) - Total Liabilities
Based on the latest financial reports, FLUOGUIDE A/S DK -1 (96X) has total liabilities worth €33.76 Million EUR (≈ $39.47 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash efficiency ratio of FLUOGUIDE A/S DK -1 to assess how effectively this company generates cash.
FLUOGUIDE A/S DK -1 - Total Liabilities Trend (2021–2025)
This chart illustrates how FLUOGUIDE A/S DK -1's total liabilities have evolved over time, based on quarterly financial data. Check FLUOGUIDE A/S DK -1 liquidity resilience to evaluate the company's liquid asset resilience ratio.
FLUOGUIDE A/S DK -1 Competitors by Total Liabilities
The table below lists competitors of FLUOGUIDE A/S DK -1 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Unigold Inc.
V:UGD
|
Canada | CA$424.21K |
|
Acelon Chemicals & Fiber Corp
TW:1466
|
Taiwan | NT$2.09 Billion |
|
Aeon Motor Co Ltd
TWO:1599
|
Taiwan | NT$838.30 Million |
|
Stefstock
JSE:SSK
|
South Africa | ZAC5.08 Billion |
|
Awilco LNG ASA
OL:ALNG
|
Norway | Nkr192.06 Million |
|
Global Education Limited
NSE:GLOBAL
|
India | Rs135.55 Million |
|
Petra Diamonds Ltd
LSE:PDL
|
UK | £325.46 Million |
|
Mount Logan Capital Inc
NEO:MLC
|
Canada | CA$1.68 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down FLUOGUIDE A/S DK -1's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 96X company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 15.15 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.62 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how FLUOGUIDE A/S DK -1's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for FLUOGUIDE A/S DK -1 (2021–2025)
The table below shows the annual total liabilities of FLUOGUIDE A/S DK -1 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €33.76 Million ≈ $39.47 Million |
+535.50% |
| 2024-12-31 | €5.31 Million ≈ $6.21 Million |
-68.54% |
| 2023-12-31 | €16.89 Million ≈ $19.75 Million |
+362.46% |
| 2022-12-31 | €3.65 Million ≈ $4.27 Million |
-75.00% |
| 2021-12-31 | €14.61 Million ≈ $17.08 Million |
-- |
About FLUOGUIDE A/S DK -1
FluoGuide A/S, a clinical stage biotechnology company, develops drugs for precision cancer surgery in Denmark. The company offers FG001, an urokinase-type plasminogen activator receptor target imaging agent, which is in Phase II clinical trial for the treatment of high-grade glioma and lung, head, and neck cancer; and functions as a photosensitizer, which is in pre-clinical stage for the treatmen… Read more